[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Unifarco SpA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100658362","ceramol-psor-cream-as-an-adjuvant-treatment-in-patients-with-mild-to-moderate-psoriasis-treated-with-narrowband-uvb-phototherapy-ceramol-psor-crema-100658362",false,"NCT07849101","Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA)","Multicenter, Prospective, Randomized, Open-Label, Controlled, Two-Arm, Parallel-Group, Superiority Clinical Investigation on the Use of Ceramol PSOR Cream in Patients With Mild-to-Moderate Plaque Psoriasis Treated With Narrowband UVB Phototherapy: CERAMOL PSOR CREMA Study","CERAMOL PSOR C","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of mild or moderate plaque psoriasis.\n* Body surface area (BSA) involvement of 3-10%, excluding palms and soles.\n* Planned treatment with narrowband UVB phototherapy as part of routine clinical practice.\n* Presence of at least one psoriasis-associated symptom (pruritus\u002Fburning, dryness\u002Ftightness) with a VAS score ≥ 3 at study entry.\n* Ability to understand and sign the Informed Consent Form\n* Willingness to use only the study product as the daily body moisturizer during the phototherapy cycle.\n\nExclusion Criteria:\n\n* Patients receiving systemic pharmacological treatment for psoriasis.\n* Patients receiving topical pharmacological treatment for psoriasis, or who discontinued such treatment less than one (1) week before enrollment.\n* Any active dermatological condition unrelated to psoriasis that could interfere with study results.\n* Cognitive impairment preventing completion of the study questionnaires.","ALL","18 Years",{"count":20,"type":21},128,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a multicenter, prospective, randomized, open-label, controlled clinical investigation to evaluate whether Ceramol PSOR cream, used as an adjuvant treatment, is superior to a comparator emollient cream in patients with mild-to-moderate plaque psoriasis undergoing narrowband UVB phototherapy. Participants apply the assigned cream topically once daily throughout one standard phototherapy cycle (36 ± 3 UVB sessions). The study assesses clinical response (PASI, body surface area), subjective symptoms (pruritus and dryness\u002Ftightness VAS), quality of life (DLQI), treatment satisfaction, and adherence to both the investigational product and phototherapy.",[27,28,29],"Psoriasis","Psoriasis; Plaque","Psoriasis Vulgaris",[27,31,32,33,34],"Narrowband UVB phototherapy","Adjuvant treatment","Emollient","Quality of life","NOT_YET_RECRUITING","2026-09-23",{"date":38,"type":39},"2026-09-30","ACTUAL",{"date":41,"type":21},"2026-10",{"date":43,"type":21},"2027-06",{"name":45,"class":46},"Unifarco SpA","INDUSTRY",3,""]